Top Qs
Timeline
Chat
Perspective
Dirloctogene samoparvovec
Experimental gene therapy From Wikipedia, the free encyclopedia
Remove ads
Dirloctocogene samoparvovec, also known as SPK-8011, is an experimental gene therapy developed for hemophilia A by Roche and Spark Therapeutics.[1][2][3][4][5][6] It uses an engineered AAV vector to cause liver cells to produce the Factor VIII blood clotting protein.[3]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads